---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011518"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:24:11.293071+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Exa-cel shows 95% TDT transfusion-free; CTX130 achieves 70% ORR in T-cell lymphoma

## Summary
- 42 of 44 TDT patients transfusion-free; all 31 SCD patients free of VOCs; follow-up up to 37.2 months.
- Exa-cel primary endpoints amended: TDT target Hb ≥9 g/dL without transfusions; SCD target no severe VOCs.
- Pediatric exa-cel studies CLIMB-141/151 now enrolling patients ages 5-11 with TDT or SCD.
- CTX130 at DL3+: ORR 70% (30% CR) in PTCL/CTCL; 90% DCR; responses across all disease compartments.
- CTX130 well tolerated: no DLTs, no GvHD, all CRS/ICANS grade 1-2; no treatment-related deaths.

## SEC filing metadata
- accession: 0000950170-22-011518
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017022011518/0000950170-22-011518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017022011518/crsp-20220611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011518
- JSON: https://secwatch.observer/filing/0000950170-22-011518.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011518.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.